메뉴 건너뛰기




Volumn 17, Issue 1, 2009, Pages 1-11

Pre-clinical QT risk assessment in pharmaceutical companies - Issues of current QT risk assessment

Author keywords

hERG; Pre clinical strategy; QT liability; QT risk

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ACETYLSALICYLIC ACID; AMOXICILLIN; ASTEMIZOLE; BEPRIDIL; CAPTOPRIL; CISAPRIDE; DIPHENHYDRAMINE; DROPERIDOL; GATIFLOXACIN; GREPAFLOXACIN; HALOFANTRINE; HALOPERIDOL; LEVOFLOXACIN; MOXIFLOXACIN; PIMOZIDE; POTASSIUM CHANNEL HERG; PRENYLAMINE; PROPRANOLOL; QUINIDINE; SERTINDOLE; SOTALOL; SPARFLOXACIN; TERFENADINE; TERODILINE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL; ZIPRASIDONE;

EID: 69549133456     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2009.17.1.1     Document Type: Review
Times cited : (13)

References (24)
  • 1
    • 27744472015 scopus 로고    scopus 로고
    • Use of preclinical assays to predict risk of drug-induced torsades de pointes
    • DOI 10.1016/j.hrthm.2004.10.032, PII S1547527104007635
    • Belardinelli, L., Shryock, J. C., Wu, L. and Song, Y. (2005). Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm. 2, S16-S22. (Pubitemid 41600827)
    • (2005) Heart Rhythm , vol.2 , Issue.11 SUPPL. 2
    • Belardinelli, L.1    Shryock, J.C.2    Wu, L.3    Song, Y.4
  • 2
    • 27744587040 scopus 로고    scopus 로고
    • Clinical trial design to evaluate the effects of drugs on cardiac repolarization: Current state of the art
    • Camm, A. J. (2005). Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm. 2, S23-S29.
    • (2005) Heart Rhythm , vol.2
    • Camm, A.J.1
  • 3
    • 33644828344 scopus 로고    scopus 로고
    • In vitro and in vivo models for testing arrhythmogenesis in drugs
    • Carlsson, L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. J. Internal. Medicine. 259, 70-80.
    • (2006) J. Internal. Medicine , vol.259 , pp. 70-80
    • Carlsson, L.1
  • 4
    • 50049083789 scopus 로고    scopus 로고
    • The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes
    • Carlsson, L. (2008). The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes Pharmacol. Ther. 119, 160-167.
    • (2008) Pharmacol. Ther. , vol.119 , pp. 160-167
    • Carlsson, L.1
  • 5
    • 0034231822 scopus 로고    scopus 로고
    • Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias
    • Cavero, I., Mestre, M., Guillon, J. M. and Crumb, W. (2003). Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1, 947-973.
    • (2003) Expert Opin. Pharmacother , vol.1 , pp. 947-973
    • Cavero, I.1    Mestre, M.2    Guillon, J.M.3    Crumb, W.4
  • 6
    • 33947540277 scopus 로고    scopus 로고
    • Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: The inseparable twins
    • Dumotier, B. M. and Georgieva, A. V. (2007). Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins. Cell Biol. Toxicol. 23, 293-302.
    • (2007) Cell Biol. Toxicol. , vol.23 , pp. 293-302
    • Dumotier, B.M.1    Georgieva, A.V.2
  • 7
  • 8
    • 50049128135 scopus 로고    scopus 로고
    • Torsades de pointes liability inter-model comparisons: The experience of the QT PRODACT initiative
    • Hashimoto, K. (2008). Torsades de pointes liability inter-model comparisons: The experience of the QT PRODACT initiative. Pharmacol. Ther. 119, 195-198.
    • (2008) Pharmacol. Ther. , vol.119 , pp. 195-198
    • Hashimoto, K.1
  • 9
    • 33747887172 scopus 로고    scopus 로고
    • ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation
    • DOI 10.1016/j.vascn.2006.05.001, PII S1056871906000608
    • Hanson, L. A., Bass, A. S., Gintant, G., Mittelstadt, S., Rampe, D. and Thomas, K. (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods. 54, 116-129. (Pubitemid 44293425)
    • (2006) Journal of Pharmacological and Toxicological Methods , vol.54 , Issue.2 , pp. 116-129
    • Hanson, L.A.1    Bass, A.S.2    Gintant, G.3    Mittelstadt, S.4    Rampe, D.5    Thomas, K.6
  • 10
    • 33644524405 scopus 로고    scopus 로고
    • Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? a review of emerging trends
    • DOI 10.1016/j.vascn.2005.07.003, PII S1056871905000936
    • Hoffmann, P. and Warner, B. (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods. 53, 87-105. (Pubitemid 43295657)
    • (2006) Journal of Pharmacological and Toxicological Methods , vol.53 , Issue.2 , pp. 87-105
    • Hoffmann, P.1    Warner, B.2
  • 11
    • 33746294441 scopus 로고    scopus 로고
    • Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias
    • DOI 10.1016/j.hrthm.2006.04.021, PII S1547527106014627
    • Liu, T., Brown, B. S., Wu, Y., Antzelevitch, C., Kowey, P. R. and Yan, G. X. (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm. 3, 948-956. (Pubitemid 44103507)
    • (2006) Heart Rhythm , vol.3 , Issue.8 , pp. 948-956
    • Liu, T.1    Brown, B.S.2    Wu, Y.3    Antzelevitch, C.4    Kowey, P.R.5    Yan, G.-X.6
  • 12
    • 48149084580 scopus 로고    scopus 로고
    • Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines
    • Lu, H. R., Vlaminckx, E., Hermans, A. N., Rohrbacher, J., Van, Ammel. K., Towart. R., Pugsley, M. and Gallacher, D. J. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154, 1427-1438.
    • (2008) Br. J. Pharmacol. , vol.154 , pp. 1427-1438
    • Lu, H.R.1    Vlaminckx, E.2    Hermans, A.N.3    Rohrbacher, J.4    Van Ammel, K.5    Towart, R.6    Pugsley, M.7    Gallacher, D.J.8
  • 14
    • 50049111108 scopus 로고    scopus 로고
    • The canine model with chronic, complete atrio-ventricular block
    • Oros, A., Beekman, J. D. and Vos, M. A. (2008). The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther. 119, 168-178.
    • (2008) Pharmacol Ther. , vol.119 , pp. 168-178
    • Oros, A.1    Beekman, J.D.2    Vos, M.A.3
  • 15
    • 48149115666 scopus 로고    scopus 로고
    • Strategies to reduce the risk of drug-induced QT interval prolongation: A pharmaceutical company perspective
    • Pollard, C. E., Valentin, J. P. and Hammond. T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br. J. Pharmacol. 154, 1538-1543.
    • (2008) Br. J. Pharmacol. , vol.154 , pp. 1538-1543
    • Pollard, C.E.1    Valentin, J.P.2    Hammond, T.G.3
  • 16
    • 0344492207 scopus 로고    scopus 로고
    • Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development
    • DOI 10.1016/S0008-6363(02)00846-5
    • Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J. and Hammond, TG. (2003). Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45. (Pubitemid 36351620)
    • (2003) Cardiovascular Research , vol.58 , Issue.1 , pp. 32-45
    • Redfern, W.S.1    Carlsson, L.2    Davis, A.S.3    Lynch, W.G.4    MacKenzie, I.5    Palethorpe, S.6    Siegl, P.K.S.7    Strang, I.8    Sullivan, A.T.9    Wallis, R.10    Camm, A.J.11    Hammond, T.G.12
  • 17
    • 48149111313 scopus 로고    scopus 로고
    • Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts
    • Sugiyama, A. (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol. 154, 1528-1537.
    • (2008) Br. J. Pharmacol. , vol.154 , pp. 1528-1537
    • Sugiyama, A.1
  • 18
    • 33645093204 scopus 로고    scopus 로고
    • QT PRODACT: In vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals
    • DOI 10.1254/jphs.QT-A3
    • Tashibu, H., Miyazaki, H., Aoki, K., Akie, Y. and Yamamoto, K. (2005). QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci. 99, 473-486. (Pubitemid 44618148)
    • (2005) Journal of Pharmacological Sciences , vol.99 , Issue.5 , pp. 473-486
    • Tashibu, H.1    Miyazaki, H.2    Aoki, K.3    Akie, Y.4    Yamamoto, K.5
  • 19
    • 33748086808 scopus 로고    scopus 로고
    • Assessing the proarrhythmic potentials of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmia
    • Thomsen M. B., Matz, J., Volders P. G. A. and Vos M. A. (2006). Assessing the proarrhythmic potentials of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmia. Pharmacol. Ther. 112, 150-170.
    • (2006) Pharmacol. Ther. , vol.112 , pp. 150-170
    • Thomsen, M.B.1    Matz, J.2    Volders, P.G.A.3    Vos, M.A.4
  • 21
    • 2542457330 scopus 로고    scopus 로고
    • Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs
    • DOI 10.1016/j.vascn.2004.03.008, PII S1056871904000164
    • Valentin, J. P., Hoffmann, P., De Clerck, F., Hammond, T. G. and Hondeghem, L. (2004). Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods. 49, 171-181. (Pubitemid 38686655)
    • (2004) Journal of Pharmacological and Toxicological Methods , vol.49 , Issue.3 , pp. 171-181
    • Valentin, J.-P.1    Hoffmann, P.2    De Clerck, F.3    Hammond, T.G.4    Hondeghem, L.5
  • 22
    • 50249105403 scopus 로고    scopus 로고
    • Early clinical development: Evaluation of drug-induced torsades de pointes risk
    • Vik, T., Pollard, C. and Sager, P. (2008). Early clinical development: Evaluation of drug-induced torsades de pointes risk. Pharmacol. Ther. 119, 210-214.
    • (2008) Pharmacol. Ther. , vol.119 , pp. 210-214
    • Vik, T.1    Pollard, C.2    Sager, P.3
  • 23
    • 0036234833 scopus 로고    scopus 로고
    • Towards a drug concentration effect relationship for QT prolongation and torsades de pointes
    • Webster, R., Leishman, D. and Walker, D. (2002). Toward a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel. 5, 116-126. (Pubitemid 34453249)
    • (2002) Current Opinion in Drug Discovery and Development , vol.5 , Issue.1 , pp. 116-126
    • Webster, R.1    Leishman, D.2    Walker, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.